# Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT00590603** · PHASE1 · TERMINATED · sponsor: **Duke University** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Arsenic Trioxide, Ascorbic Acid and Bortezomib

## Key facts

- **NCT ID:** NCT00590603
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Poor accrual - terminated during Phase I; Phase II never started.
- **Last updated:** 2014-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590603, "Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00590603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*